Business
Update on Lisinopril Contract
Update on Lisinopril Contract.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n Hikma Pharmaceuticals Plc\n21 November 2007\n\n\n Update on lisinopril contract\n\nLondon, 21 November 2007 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)\n('Hikma') announces that it is still awaiting the re-issuance of the\nsolicitation for the supply of lisinopril from the US Department of Veterans\nAffairs. Once this solicitation is issued, Hikma intends to participate as\nnormal in the bidding process. Hikma continues to supply lisinopril under its\nexisting contract with the Department of Veterans Affairs, which runs through to\n20 December 2007.\n\n\n - ENDS -\n\nEnquiries:\n\nHikma Pharmaceuticals PLC +44 20 7399 2670\nSusan Ringdal, Investor Relations Director\n\nBrunswick Group LLP +44 20 7404 5959\nJon Coles / Justine McIlroy / Alex Tweed\n\n\nNotes to Editors\n\nAbout Hikma\n\nHikma Pharmaceuticals PLC is a fast growing multinational group focused on\ndeveloping, manufacturing and marketing a broad range of both branded and\nnon-branded generic and in-licensed products. Hikma operates through three\nbusinesses: 'Branded', 'Injectables' and 'Generics', based principally in the\nMiddle East and North Africa ('MENA'), where it is a market leader and sells\nacross 18 countries, the United States and Europe. In the year ended 31\nDecember 2006, Hikma achieved revenues of $317 million (2005: $262 million) and\nprofit attributable to shareholders was $55 million (2005: $44 million). At 31\nDecember 2006, the Group had over 2,400 employees. For news and other\ninformation, please visit www.hikma.com\n\n\n\n This information is provided by RNS\n The company news service from the London Stock Exchange \n ","length":1803,"tagName":"div"}]